Pharmaceutical News

RSS

WM Holdings, Full Motion Beverage sign LOI for GX Supplements

Full Motion Beverage, Inc. a new age beverage company has signed a letter of intent (LOI) with WM Holdings, LLC, makers of GX Supplements.

23 Jun 2012

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

AMAG Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

23 Jun 2012

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Apply the ointment, light on, light off - that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy.

23 Jun 2012

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).

22 Jun 2012

Abbott challenges copies of its biologic drugs

If the challenge succeeds, less-expensive versions of complex biologic drugs couldn't go on sale in the U.S. for years, and consumers may never have access to facsimiles of existing treatments such as Abbott's rheumatoid arthritis therapy Humira.

22 Jun 2012

No legal recourse because generic drug caused injury

Carrie Scott went in to the hospital for abnormal bleeding. Days later she returned home without her hand and forearm. The generic form of Phenergan was given improperly, apparently from an inadequate warning label. Scott has no legal recourse because a generic drug caused her injury, rather than its brand-name equivalent.

22 Jun 2012

Patients taking common blood pressure drug show symptoms of celiac disease

Mayo Clinic researchers have discovered an association between a commonly prescribed blood pressure drug, Olmesartan, and severe gastrointestinal issues such as nausea, vomiting, diarrhea, weight loss and electrolyte abnormalities -- symptoms common among those who have celiac disease. The findings are published online today in the medical journal Mayo Clinic Proceedings.

22 Jun 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

Fructose may not be as bad for us as previously thought

A new study by researchers at St. Michael's Hospital suggests that fructose may not be as bad for us as previously thought and that it may even provide some benefit.

22 Jun 2012

Depomed acquires all rights to Zipsor from Xanodyne

Depomed, Inc. today announced that it has acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.

22 Jun 2012

Link between Olmesartan drug and severe GI issues

22 Jun 2012

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.

22 Jun 2012

Lead 8A analog can treat osteosarcoma in children

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

22 Jun 2012

Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.

22 Jun 2012

CRN releases 'The Benefits of Nutritional Supplements'

The Council for Responsible Nutrition (CRN), the dietary supplement industry's leading trade association, today released its comprehensive report, The Benefits of Nutritional Supplements.

21 Jun 2012

Genetics play a significant role in determining side effects of opiates

Genetics play a significant role in determining which patients will suffer the most from the disturbing side effects of opiates, commonly prescribed painkillers for severe to moderate pain, according to a new Stanford University School of Medicine study, which pinpoints nausea, slowed breathing and potential for addiction as heritable traits.

21 Jun 2012

Foods fortified with folic acid can prevent neural tube defects

Wheat flour milled in Nigeria will soon be fortified with folic acid, a B vitamin known for preventing serious or fatal birth defects of the spine and brain. Women who may become pregnant are encouraged to daily choose foods fortified with this essential vitamin because it can prevent the majority of these devastating birth defects known as neural tube defects.

21 Jun 2012

Simple new procedure can remove impurities from pharmaceuticals

Scientists are reporting development of a simple new procedure for removing almost 98 percent of an important impurity that can contaminate prescription drugs and potentially increase the risk for adverse health effects in patients.

21 Jun 2012

$Study tests link between anesthesia type, complications and mortality after hip fracture surgery$

Study tests link between anesthesia type, complications and mortality after hip fracture surgery

Anesthesia type may affect complications and mortality after hip fracture surgery, according to a new study in the July issue of Anesthesiology. The Perelman School of Medicine at the University of Pennsylvania study tested the association between regional versus general anesthesia, and pulmonary and cardiovascular complications and mortality.

21 Jun 2012

FDA grants Orphan Drug Designation to Medgenics’ INFRADURE Biopump

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its INFRADURE Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D.

21 Jun 2012